Objective. Glucagon-like peptide-1 (GLP-1) has many effects on glucose homeostasis, and GLP-1 receptors are broadly represented in many tissues including the brain. Recent research in rodents ...

Websites that sell compounded glucagon-like peptide-1 receptor agonists (GLP-1 RAs) often partially inform or misinform ...

HealthDay News — Glucagon-like peptide 1 receptor agonist (GLP-1 RA) use is not associated with an increased risk for thyroid cancer over the short term, according to a study published online January ...

This cohort study found that key sociodemographic, health care, and clinical factors are associated with receipt of semaglutide, a novel glucagon-like peptide-1 (GLP-1) receptor agonist medication, in ...

For people with diabetes, the use of glucagon-like peptide-1 receptor agonists (GLP-1 RAs) is associated with a reduc ...

This cohort study found that key sociodemographic, health care, and clinical factors are associated with receipt of semaglutide, a ...

The market for GLP-1 drugs is projected to exceed $200 billion in annual sales by 2031, according to Morningstar Equity Research. Current market leaders include Novo Nordisk NVO and Eli Lilly LLY with ...

The following is a summary of “Treatment of Hypothalamic Obesity With GLP-1 Analogs,” published in the November 2024 issue of Endocrinology by Dimitri and Roth. Damage to hypothalamic nuclei or ...

Losing weight on a GLP-1 medication can have emotional and physical effects. Some changes are easier to handle than others, ...

Ke, X. and Ma, T. (2025) Protective Effect of Liraglutide on Early Renal Fibrosis in Diabetes Mice. Journal of Biosciences and Medicines, 13, 84-91. doi: 10.4236/jbm.2025.131008 .

The glucagon-like peptide-1 receptor (GLP-1R) market experienced significant growth in 2023, generating $37.2 billion in ...

Drugs targeting the glucagon-like peptide-1 receptor (GLP-1R) demonstrated remarkable success ... three smaller biotechs – Viking Therapeutics, Altimmune, and Structure Therapeutics – are emerging as ...